Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
O. Abani,A. Abbas,497 Authors,M. Baxter
2021 · DOI: 10.1016/S0140-6736(21)00676-0
The Lancet · 1,538 Citations
TLDR
In hospitalised COVID-19 patients with hypoxia and systemic inflammation, tocilizumab improved survival and other clinical outcomes, seen regardless of the amount of respiratory support and were additional to the benefits of systemic corticosteroids.
Cited Papers
Citing Papers